8-KOther Events

JOHNSON & JOHNSON 8-K Report (Jan 20, 2004)

Filed January 20, 2004For Securities:JNJ

Summary

Johnson & Johnson (J&J) filed an 8-K report on January 20, 2004, to announce its fourth quarter and fiscal year 2003 sales and earnings results, which ended on December 28, 2003. The report includes a press release detailing these financial outcomes. J&J provided investors with both GAAP and non-GAAP financial information, notably earnings before taxes, net earnings, and diluted earnings per share, excluding charges related to in-process research and development (IPR&D) from business combinations. The company believes this exclusion offers a clearer view of ongoing operational performance.

Key Highlights

  • 1J&J announced fourth quarter and full fiscal year 2003 sales and earnings results.
  • 2The financial results cover the period ending December 28, 2003.
  • 3The report was filed on January 20, 2004.
  • 4J&J provided both GAAP and non-GAAP financial disclosures to investors.
  • 5Key non-GAAP metrics exclude in-process research and development (IPR&D) charges.
  • 6The exclusion of IPR&D is intended to provide insight into ongoing business operations.

Frequently Asked Questions

The primary purpose of this 8-K filing is to announce Johnson & Johnson's (J&J) fourth quarter and full fiscal year 2003 sales and earnings results. It includes a press release that provides these financial details for the period ending December 28, 2003.

J&J provided both Generally Accepted Accounting Principles (GAAP) and non-GAAP financial information. This included earnings before taxes, net earnings, and diluted earnings per share.

Johnson & Johnson provided non-GAAP measures, specifically excluding charges related to in-process research and development (IPR&D) from business combinations, to offer investors a clearer perspective on the company's ongoing business operations. They believe this exclusion helps in evaluating underlying performance.

IPR&D charges mentioned in the filing relate to business combination transactions. Johnson & Johnson excludes these charges from certain financial metrics to present a view of operations that is not impacted by these specific deal-related accounting treatments.